摘要
Immunotherapy has demonstrated the potential to cure melanoma,while the current response rate is still unsatisfactory in clinics.Extensive evidence indicates the correlation between the eficacy and pre-existing T-cell in tumors,whereas the baseline T-cell infiltration is lacking in low-response melanoma patients.
出处
《Research》
SCIE
EI
CSCD
2023年第2期139-157,共19页
研究（英文）
基金
This work was supported by National Natural Science Foundation of China(Nos.U1903125,31800979)
Natural ScienceFoundationof HunanProvinceinChina(2021JJ20084,2021J20092)
the Science and Technology Innovation Program of Hunan Province(2021RC3020,2020RC2010)
This study was also supported by National Key Research and Development Program of China(2019YFA0111600 and 2019YFE0120800)
the Natural Science Foundation of China for Outstanding Young Scholars(82022060)
the Youth Talent Program of Hunan Province(2019RS2009)
the Natural Science Foundation of Hunan Province for Outstanding Young Scholars(2019JJ30040)
Innovation-Driven Project of Central South University(2020CX043)
China Postdoctoral Science Foundation Funded Project(2021M693558,2022T150741).
